SEC Form 4 · accession 0000899243-16-012604
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanofi
10% Owner
Period of report
Feb 1, 2016
Accepted (ET)
Feb 3, 2016 · 7:00 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2016 | P | 205,030 | $69.75 | A | 10,256,633 | I | Via wholly-owned subsidiary, Genzyme Corp. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014.
Remarks
Exhibit 24 - Power of Attorney